Product Name

selexipag cas 475086-01-2

Basic Information

CAS No:475086-01-2
Molecular Formula:C26H32N4O4S
Molecular Weight:496.622
Remarks:Factory direct sales

selexipag Properties

Item

Specifications

Appearance

White Powder

Purity/%

99.9%

Melting point/℃113.36
PSA127.1
density(Kg/m³)1200(rough estimate)
refractive index1.579
Flash point/℃299.3
storage temproom temperature

selexipag USES

selexipag tablets have the effects of anti-platelet aggregation, inhibition of thrombosis, improvement of cerebrovascular circulation, reduction of stroke risk and prevention of cerebral infarction.
1. Anti-platelet aggregation

Because the active ingredient in the drug inhibits adenosine diphosphate receptors, preventing their mediated cell activation and adhesion, platelet aggregation is reduced. This effect can be used to treat atherosclerosis, coronary atherosclerotic heart disease and other diseases. Patients may take this product as directed to reduce symptoms.

2. Inhibit thrombosis

Because the drug has the effect of blocking P2Y12 receptor, so that platelets can not be activated and participate in the clotting process, so as to achieve the purpose of inhibiting thrombosis. For those at high risk of bleeding or receiving anticoagulant therapy, this product should be used with caution to avoid aggravating bleeding tendencies.

3. Improve cerebrovascular circulation
By expanding cerebral vessels, increase cerebral blood flow and improve cerebral vascular circulation function. It is suitable for dizziness and insufficient blood supply caused by ischemic cerebrovascular disease. Dosage should be adjusted individually, following the doctor’s guidance.

4. Reduce stroke risk

The drug can effectively inhibit the activation and aggregation of platelets and reduce the viscosity of blood, thus reducing the formation of thrombus and reducing the incidence of stroke. It is recommended that elderly patients over 65 years of age take this product for a long time to prevent the occurrence of stroke events.

5. Prevent cerebral infarction

The drug can effectively inhibit platelet activation and aggregation, prevent thrombosis, and thus prevent the occurrence of cerebral infarction.

selexipag Packaging

Packing: 25Kg,100Kg,200Kg,1000Kg/Drum

selexipag storage

  1. Store barreled products in a cool, ventilated warehouse; keep away from

fire and heat sources. The warehousing temperature does not exceed 30 ℃, and the relative

humidity does not exceed 80%. Keep the container sealed; products should be stored separately

from oxidants, reducing agents, etc., and should not be mixed; be equipped with fire-fighting

equipment of appropriate variety and quantity; the storage area should be equipped with

equipment for emergency treatment of leakage and suitable containment materials;

  1. Store in a special storage tank; keep away from fire and heat sources; there is fire-fighting foam

for a fire emergency, and the tank area is equipped with equipment for the emergency treatment of

leakage.

  1. Shelf life: The shelf life of this product is 6 months.

product list

Contact us

Focus on industrial, agricultural, daily life and other chemical development